What is Albireo Pharma, Inc?
Albireo Pharma, Inc. operates as a specialized biopharmaceutical entity dedicated to the research and development of novel bile acid modulators. By targeting rare pediatric and adult liver conditions, the company has carved out a distinct niche in the global healthcare landscape. Headquartered in Boston, Massachusetts, with critical operational infrastructure in Gothenburg, Sweden, Albireo leverages a cross-continental research framework to advance its clinical pipeline. The firm's focus on bile acid biology positions it as a leader in developing therapeutic interventions for conditions that have historically lacked effective treatment options, thereby enhancing its value proposition for both patients and institutional stakeholders.
How much funding has Albireo Pharma, Inc raised?
Albireo Pharma, Inc has raised a total of $115M across 1 funding round:
Private Equity
$115M
Private Equity (2022): $115M with participation from Sagard
Key Investors in Albireo Pharma, Inc
Sagard
Sagard Holdings is a multi-strategy alternative asset manager that provides flexible capital solutions and deep industry expertise to support the growth of innovative enterprises.
What's next for Albireo Pharma, Inc?
Following this major strategic investment, Albireo Pharma is well-positioned to accelerate its clinical development programs and expand its commercial reach. The influx of capital provides the necessary runway to navigate complex regulatory environments and scale manufacturing capabilities for its lead assets. As the company transitions into a more mature phase of its lifecycle, the focus will likely shift toward optimizing market access and deepening its research into next-generation bile acid modulators. By maintaining its commitment to scientific rigor and operational excellence, Albireo is poised to sustain its growth trajectory and potentially redefine the standard of care for rare liver diseases on a global scale.
See full Albireo Pharma, Inc company page
